Key result
When dosed according to published guidelines, 66% (25/38) of pediatric patients receiving enoxaparin for thrombosis achieved therapeutic anti-Xa levels after two doses.
Why the study?
Does enoxaparin dosed according to published guidelines achieve therapeutic anticoagulation in pediatric patients with thrombosis?
Population
Pediatric patients receiving treatment doses of enoxaparin for thrombosis at a tertiary care pediatric…
Design
Cohort
Follow-up
After two doses
Authors
Loading...
Supports anti-Xa monitoring with guideline enoxaparin dosing in children; leaves open refined regimens for infants and cardiac/renal patients.
Cohort (n=38)
No
Does enoxaparin dosed according to published guidelines achieve therapeutic anticoagulation in pediatric patients with thrombosis?
Published pediatric dosage guidelines for enoxaparin achieve therapeutic anticoagulation in most patients, but routine anti-Xa monitoring remains necessary, especially in infants under 2 months and those with cardiac or renal disease.
Ho et al. (2004) conducted a cohort in thrombosis (n=38). Enoxaparin was evaluated on anti-Xa levels within the recommended therapeutic range (0.5-1.0 [+/- 10%] U/mL) after two doses. When dosed according to published guidelines, 66% (25/38) of pediatric patients receiving enoxaparin for thrombosis achieved therapeutic anti-Xa levels after two doses.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: